WO2022140528A1 - Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) - Google Patents
Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) Download PDFInfo
- Publication number
- WO2022140528A1 WO2022140528A1 PCT/US2021/064831 US2021064831W WO2022140528A1 WO 2022140528 A1 WO2022140528 A1 WO 2022140528A1 US 2021064831 W US2021064831 W US 2021064831W WO 2022140528 A1 WO2022140528 A1 WO 2022140528A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- methyl
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title abstract description 73
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title abstract description 72
- 239000003112 inhibitor Substances 0.000 title abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 255
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 174
- 239000000203 mixture Substances 0.000 claims description 112
- -1 HO- Chemical group 0.000 claims description 79
- 150000003839 salts Chemical class 0.000 claims description 74
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 69
- 125000001072 heteroaryl group Chemical group 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- 150000003973 alkyl amines Chemical class 0.000 claims description 54
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 53
- 229910052805 deuterium Inorganic materials 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 230000003287 optical effect Effects 0.000 claims description 42
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 39
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 37
- YFGSYVYVMKBGBK-RJSMTVDQSA-N 2-deuterio-3-[[(2S,3S)-5-methoxy-3-(6-methoxypyridin-3-yl)-2-methyl-2,3-dihydro-1,4-benzodioxin-7-yl]methyl]imidazo[4,5-b]pyridine Chemical compound [2H]C1=NC2=CC=CN=C2N1CC(C=C1OC)=CC(O[C@H]2C)=C1O[C@H]2C(C=N1)=CC=C1OC YFGSYVYVMKBGBK-RJSMTVDQSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 28
- 230000001404 mediated effect Effects 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 6
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 73
- 239000000243 solution Substances 0.000 description 72
- 102100036826 Aldehyde oxidase Human genes 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 65
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 52
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 52
- 241000282414 Homo sapiens Species 0.000 description 51
- 229940125961 compound 24 Drugs 0.000 description 50
- 125000005843 halogen group Chemical group 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 230000000638 stimulation Effects 0.000 description 48
- 238000011534 incubation Methods 0.000 description 46
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 40
- 238000004949 mass spectrometry Methods 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 36
- 210000000274 microglia Anatomy 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- 238000003556 assay Methods 0.000 description 30
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 29
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 29
- 239000003814 drug Substances 0.000 description 29
- 210000003494 hepatocyte Anatomy 0.000 description 29
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000023611 glucuronidation Effects 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 230000002025 microglial effect Effects 0.000 description 21
- 229960002474 hydralazine Drugs 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 230000004060 metabolic process Effects 0.000 description 19
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 16
- 230000035699 permeability Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- 108091011896 CSF1 Proteins 0.000 description 13
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 13
- 238000011097 chromatography purification Methods 0.000 description 13
- 229910052681 coesite Inorganic materials 0.000 description 13
- 229910052906 cristobalite Inorganic materials 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 13
- 239000010931 gold Substances 0.000 description 13
- 229910052737 gold Inorganic materials 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 13
- 229910052682 stishovite Inorganic materials 0.000 description 13
- 229910052905 tridymite Inorganic materials 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 230000033444 hydroxylation Effects 0.000 description 12
- 238000005805 hydroxylation reaction Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000014564 chemokine production Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 230000037353 metabolic pathway Effects 0.000 description 10
- 230000000926 neurological effect Effects 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 10
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 9
- 150000001450 anions Chemical class 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 229940127271 compound 49 Drugs 0.000 description 8
- 238000010520 demethylation reaction Methods 0.000 description 8
- 201000002491 encephalomyelitis Diseases 0.000 description 8
- 229930182480 glucuronide Natural products 0.000 description 8
- 150000008134 glucuronides Chemical class 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010081690 Pertussis Toxin Proteins 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- JUJWROOIHBZHMG-QYKNYGDISA-N 2-deuteriopyridine Chemical compound [2H]C1=CC=CC=N1 JUJWROOIHBZHMG-QYKNYGDISA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- YFGSYVYVMKBGBK-LHSJRXKWSA-N COC1=CC=C(C=N1)[C@@H]1OC2=C(OC)C=C(CN3C=NC4=C3N=CC=C4)C=C2O[C@H]1C Chemical compound COC1=CC=C(C=N1)[C@@H]1OC2=C(OC)C=C(CN3C=NC4=C3N=CC=C4)C=C2O[C@H]1C YFGSYVYVMKBGBK-LHSJRXKWSA-N 0.000 description 6
- 101710091439 Major capsid protein 1 Proteins 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 6
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- 102000003849 Cytochrome P450 Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000002390 adhesive tape Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 239000012470 diluted sample Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 238000010079 rubber tapping Methods 0.000 description 5
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000012089 stop solution Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- KFZMGEQAYNKOFK-PIODKIDGSA-N 1,1,1,2,3,3,3-heptadeuterio-2-deuteriooxypropane Chemical compound [2H]OC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H] KFZMGEQAYNKOFK-PIODKIDGSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108700013048 CCL2 Proteins 0.000 description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 4
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 4
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013584 assay control Substances 0.000 description 4
- 229940045348 brown mixture Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000017858 demethylation Effects 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000007833 oxidative deamination reaction Methods 0.000 description 4
- 230000001769 paralizing effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000001907 polarising light microscopy Methods 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 229940054967 vanquish Drugs 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 241000588832 Bordetella pertussis Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-DICFDUPASA-N dideuteriomethanol Chemical compound [2H]C([2H])O OKKJLVBELUTLKV-DICFDUPASA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 2
- VUESZXUUUWLCMZ-LHSJRXKWSA-N 2-[(1S,2S)-1-hydroxy-1-(6-methoxypyridin-3-yl)propan-2-yl]oxy-4-(imidazo[4,5-b]pyridin-3-ylmethyl)-6-methoxyphenol Chemical compound C[C@@H]([C@H](C(C=N1)=CC=C1OC)O)OC(C=C(CN1C2=NC=CC=C2N=C1)C=C1OC)=C1O VUESZXUUUWLCMZ-LHSJRXKWSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UPTBYLYNRRWGLK-UHFFFAOYSA-N 2-[5-(imidazo[4,5-b]pyridin-3-ylmethyl)-3-methoxy-2-phenylmethoxyphenoxy]-1-(6-methoxypyridin-3-yl)propan-1-one Chemical compound CC(C(C(C=N1)=CC=C1OC)=O)OC(C=C(CN1C2=NC=CC=C2N=C1)C=C1OC)=C1OCC1=CC=CC=C1 UPTBYLYNRRWGLK-UHFFFAOYSA-N 0.000 description 2
- OZHBNEJVZLWGQG-UHFFFAOYSA-N 2-bromo-1-(6-methoxypyridin-3-yl)propan-1-one Chemical compound BrC(C(=O)C=1C=NC(=CC=1)OC)C OZHBNEJVZLWGQG-UHFFFAOYSA-N 0.000 description 2
- BVPOSMJCIRQLTQ-XCLFUZPHSA-N 2-bromo-3-[[(2R,3R)-5-methoxy-3-(6-methoxypyridin-3-yl)-2-methyl-2,3-dihydro-1,4-benzodioxin-7-yl]methyl]imidazo[4,5-b]pyridine Chemical compound C[C@H]1OC(C=C(CN2C(Br)=NC3=CC=CN=C23)C=C2OC)=C2O[C@@H]1C(C=N1)=CC=C1OC BVPOSMJCIRQLTQ-XCLFUZPHSA-N 0.000 description 2
- BVPOSMJCIRQLTQ-RNODOKPDSA-N 2-bromo-3-[[(2S,3S)-5-methoxy-3-(6-methoxypyridin-3-yl)-2-methyl-2,3-dihydro-1,4-benzodioxin-7-yl]methyl]imidazo[4,5-b]pyridine Chemical compound C[C@@H]1OC(C=C(CN2C(Br)=NC3=CC=CN=C23)C=C2OC)=C2O[C@H]1C(C=N1)=CC=C1OC BVPOSMJCIRQLTQ-RNODOKPDSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-M 3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 101000916629 Mus musculus Macrophage colony-stimulating factor 1 Proteins 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229940087098 Oxidase inhibitor Drugs 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- LBWSXSNURGEMLE-KCJKRLIRSA-N [2H]C([2H])(C1(N)NC=CC=C1N)C(C=C1OC)=CC(O[C@H]2C)=C1O[C@H]2C(C=N1)=CC=C1OC Chemical compound [2H]C([2H])(C1(N)NC=CC=C1N)C(C=C1OC)=CC(O[C@H]2C)=C1O[C@H]2C(C=N1)=CC=C1OC LBWSXSNURGEMLE-KCJKRLIRSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000011157 data evaluation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 102000046768 human CCL2 Human genes 0.000 description 2
- 102000053925 human CSF1 Human genes 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000012006 liquid chromatography with tandem mass spectrometry Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007884 metabolite profiling Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000006756 microglial proliferation Effects 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 2
- 229960004010 zaleplon Drugs 0.000 description 2
- WDYGPMAMBXJESZ-SFHVURJKSA-N (2s)-1,1-bis(4-methoxyphenyl)-3-methylbutane-1,2-diamine Chemical compound C1=CC(OC)=CC=C1C(N)([C@@H](N)C(C)C)C1=CC=C(OC)C=C1 WDYGPMAMBXJESZ-SFHVURJKSA-N 0.000 description 1
- BDERNNFJNOPAEC-RIZALVEQSA-N 1,1,1,2,2,3,3-heptadeuterio-3-deuteriooxypropane Chemical compound [2H]OC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H] BDERNNFJNOPAEC-RIZALVEQSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- QPQZLVUOFQEHBY-UHFFFAOYSA-N 1-(6-methoxypyridin-3-yl)propan-1-one Chemical compound CCC(=O)C1=CC=C(OC)N=C1 QPQZLVUOFQEHBY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000002223 1H--13C heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000004701 1H-13C HSQC Methods 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- BVPOSMJCIRQLTQ-MOAOHQBWSA-N 2-bromo-5-deuterio-3-[[(2S,3S)-5-methoxy-3-(6-methoxypyridin-3-yl)-2-methyl-2,3-dihydro-1,4-benzodioxin-7-yl]methyl]imidazo[4,5-b]pyridine Chemical compound [2H]C(N=C1N2CC(C=C3OC)=CC(O[C@H]4C)=C3O[C@H]4C(C=N3)=CC=C3OC)=CC=C1N=C2Br BVPOSMJCIRQLTQ-MOAOHQBWSA-N 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 1
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-VMNATFBRSA-N 3-deuteriopyridine Chemical compound [2H]c1cccnc1 JUJWROOIHBZHMG-VMNATFBRSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- INKJIWXVLWIENL-UHFFFAOYSA-N 5-bromo-1h-imidazo[4,5-b]pyridine Chemical compound BrC1=CC=C2NC=NC2=N1 INKJIWXVLWIENL-UHFFFAOYSA-N 0.000 description 1
- BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150053137 AIF1 gene Proteins 0.000 description 1
- 101150006240 AOX2 gene Proteins 0.000 description 1
- 101150070510 AOX3 gene Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101150008289 Aox4 gene Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 210000001288 CNS macrophage Anatomy 0.000 description 1
- YFGSYVYVMKBGBK-SZNDQCEHSA-N COC1=CC=C(C=N1)[C@H]1OC2=C(OC)C=C(CN3C=NC4=C3N=CC=C4)C=C2O[C@@H]1C Chemical compound COC1=CC=C(C=N1)[C@H]1OC2=C(OC)C=C(CN3C=NC4=C3N=CC=C4)C=C2O[C@@H]1C YFGSYVYVMKBGBK-SZNDQCEHSA-N 0.000 description 1
- AXCUPSHCKNAXIY-ZUZCIYMTSA-N C[C@@H]([C@H](C(C=N1)=CC=C1OC)O)OC(C=CC=C1OC)=C1O Chemical compound C[C@@H]([C@H](C(C=N1)=CC=C1OC)O)OC(C=CC=C1OC)=C1O AXCUPSHCKNAXIY-ZUZCIYMTSA-N 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RCXUGMHAWQEBHR-UHFFFAOYSA-N N1=CN(C2=NC=CC=C21)CC=1C=C(C(=C(C=1)O)OCC1=CC=CC=C1)OC Chemical compound N1=CN(C2=NC=CC=C21)CC=1C=C(C(=C(C=1)O)OCC1=CC=CC=C1)OC RCXUGMHAWQEBHR-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YZRXVEHASHFIMD-UHFFFAOYSA-N OC1=C(C=C(C(=O)OC)C=C1OC)OC(C(C=1C=NC(=CC=1)OC)O)C Chemical compound OC1=C(C=C(C(=O)OC)C=C1OC)OC(C(C=1C=NC(=CC=1)OC)O)C YZRXVEHASHFIMD-UHFFFAOYSA-N 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- DLGYNVMUCSTYDQ-UHFFFAOYSA-N azane;pyridine Chemical compound N.C1=CC=NC=C1 DLGYNVMUCSTYDQ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000004989 dicarbonyl group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 102000053683 human AOX1 Human genes 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FBDWCTWJJMORIU-UHFFFAOYSA-N magnesium;hexahydrate Chemical compound O.O.O.O.O.O.[Mg] FBDWCTWJJMORIU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007388 microgliosis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 229950001457 pexidartinib Drugs 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- ADME absorption, distribution, metabolism and/or excretion
- Aldehyde oxidase is a cytosolic molybdenum-containing enzyme involved in the biotransformation of numerous drugs.
- the challenge represented by AO-mediated metabolism is driven by several overlapping factors, including the complex biology of the enzyme and the widespread use of structural motifs that are AO substrates (e.g., azaheterocycles and amides.) See, e.g., Manevski, N. et al, Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery, J. Med. Chem. 2019, 62, 10955-10994.
- differences in AO-mediated metabolism not only between species, but also between individuals, contribute to variability in exposure and complicate human dose selection.
- CSF-1R inhibitor compounds as set forth in WO 2017/015267 that are substituted with deuterium can have improved ADME properties.
- CSF-1R inhibitor compounds substituted with deuterium at specific positions have improved ADME properties, in particular, significant resistance to AO degradation, thus potentially improving the drug efficacy and the exposure of the drug in vivo.
- Disclosed herein are deuterated Colony Stimulating Factor-1 Receptor inhibitors (“CSF-1R inhibitors”) that are resistant to enzymatic degradation in vivo.
- the CSF-1R inhibitors of this disclosure are small molecule compounds that are capable of penetrating the blood-brain barrier to reach the central nervous system (CNS.) Because these compounds are advantageously able to penetrate the blood-brain barrier (a highly desirable property in neurological indications), the compounds need to be able to exhibit sufficient absorption, metabolism, distribution, and excretion (ADME) properties in order to ensure proper dosing. Metabolism issues can include rapid metabolism as well as metabolic degradation, both of which can lead to toxicities and/or suboptimal dosing of the active agent.
- This disclosure relates to deuterated CSF-1R inhibitors and to the use of deuterated CSF-1R inhibitors and pharmaceutical compositions to treat disease, comprising CSF-1R inhibitors that have a surprising reduction of AO degradation and high efficacy as CSF-1R inhibitors to treat disease.
- Such compounds include compounds of Formula (I): and/or or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein: the dashed lines represent optional double bonds;
- X 1 is C, N, or CR 7 ;
- X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 are each independently selected from N, NR 7 , or CR 7 ;
- X 8 and X 9 are each independently selected from N or C; wherein each R 7 is independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 2 -C 10 )alkylnyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 2 -C 10 )alkynylamine, C(O)-, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl-, COOH-(C 3 -C 10 )cycloalkyl-, (C 1 -C 10 )alkoxy-, R 8 -(C 1 -C 10
- T 1 , T 2 , and T 3 is each independently selected from are each independently selected from N or CR 10 , wherein each R 10 is independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 2 -C 10 )alkylnyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 2 -C 10 )alkynylamine, C(O)-, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl-, COOH-(C 3 -C 10 )cycloalkyl-, (C 1 -C 10 )alkoxy-,
- Y 1 is O, NR 12 , or CR 12 R 13 , wherein R 12 is absent or R 12 and R 13 are each independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 1 -C 3 )alkynylamine, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl, COOH-(C 3 -C 10 )cycloalkyl, (C 1 -C 10 )alkoxy-, (C 1 -C 10 )alkoxy-(C 1 -C 10 )alkyl
- R 5 is absent or selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 1 -C3)alkynylamine, (C 1 -C 10 )alkoxy-, (C 1 -C 10 )alkoxy-(C 1 -C 10 )alkyl-, (C 3 -C 10 )cycloalkyl-O-, (C 2 -C 9 )heterocycloalkyl-O-, (C 6 -C 14 )aryl-O-, (C 2 -C 9 )heteroaryl-O-, HO-, halo, and H 2
- R 6 is selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 2 -C 10 )alkylnyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 2 -C 10 )alkynylamine, C(O)-, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl-, COOH-(C 3 -C 10 )cycloalkyl-, (C 1 -C 10 )alkoxy-, R 14 -(C 1 -C 10 )alkyl-, R 14 -(C 3 -C 10 )cycl
- Z 1 is selected from H, halo, (C 1 -C 10 )alkyl, (C 2 -C 9 )heteroalkyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 2 -C 10 )alkynylamine, (C 1 -C 10 )alkoxy-, or H 2 N-;
- Y 2 is O, S, NR 17 , or CR 17 R 18 , and wherein R 17 is absent or R 17 and R 18 are each independently selected from H, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 1 -C 3 )alkynylamine, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl, COOH-(C 3 -C 10 )cycloalkyl, (C 1 -C 10 )alkoxy-, (C 1 -C 10 )alkoxy-(C 1 -C 10 )alky
- the disclosure relates to compounds of Formula (I): and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein: the dashed lines represent optional double bonds;
- X 1 is C, N, or CR 7 ;
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 are each independently selected from N, NR 7 , or CR 7 ;
- X 8 , and X 9 are each independently selected from N or C; wherein each R 7 is independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl,(C 2 -C 9 )heteroaryl, (C 2 -C 10 )alkynylamine, (C 1 -C 10 )alkyl-C(O)O-,(C 1 -C 10 )alkoxy-,
- Y 1 is O, NR 12 , or CR 12 R 13 ; wherein R 12 is absent or R 12 and R 13 are each independently selected from H, D, (C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 1 -C 3 )alkynylamine, (C 1 -C 10 )alkoxy-, (C 1 -C 10 )alkoxy-(C 1 -C 10 )alkyl-, HO-, halo, and H 2 N-;
- R 1 and R 2 are each independently selected from H, D, (C 1 -C 10 )alkyl, HO-, halo, and H 2 N;
- R 5 is absent or selected from H, D, (C 1 -C 10 )alkyl, HO-, halo, and H 2 N-;
- R 6 is selected from D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, R 14 -(C 3 -C 10 )cycloalkyl, R 14 -(C 6 -C 14 )aryl, R 14 -(C 2 -C 9 )heteroaryl, and R 14 -(C 1 -C 10 )alkylamine; wherein R 14 is each independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine
- Z 1 is selected from H, halo, and (C 1 -C 10 )alkyl
- Y 2 is O, NR 17 , or CR 17 R 18 ; wherein R 17 is absent or R 17 and R 18 are each independently selected from H, (C 1 -C 10 )alkyl, HO-, halo, and H 2 N-; wherein at least one of R 7 , R 1 , or R 2 is D.
- the disclosure relates to compounds of Formula (I’): and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein: the dashed lines represent optional double bonds;
- A is selected from H and D;
- X 3 is CR 3 wherein R 3 is selected from H and D;
- X 4 is CR 4 wherein R 4 is selected from H, D, and R 7 ;
- X 5 is CR 5 wherein R 5 is selected from H and D, wherein at least one of A, R 3 , R 4 , and R 5 is D.
- This disclosure also relates to pharmaceutical formulations comprising deuterated CSF-1R inhibitors and to the use, for treating disease, of deuterated CSF-1R inhibitors and pharmaceutical compositions comprising CSF-1R inhibitors. Further disclosed herein is the use of deuterated CSF-1R inhibitors and pharmaceutical compositions comprising deuterated CSF-1R inhibitors that are aldehyde oxidase degradation -resistant, for treating immune-mediated diseases, including multiple sclerosis, lupus nephritis, and rheumatoid arthritis, and neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and Huntington’s disease.
- ALS amyotrophic lateral sclerosis
- MSA multiple system atrophy
- PSP progressive supranuclear palsy
- Huntington’s disease Huntington’s disease.
- deuterium modification With deuterium modification, one attempts to slow the CYP -mediated metabolism of a drug or to reduce the formation of undesirable metabolites by replacing one or more hydrogen atoms with deuterium atoms.
- Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Compared to hydrogen, deuterium forms stronger bonds with carbon. In select cases, the increased bond strength imparted by deuterium can positively impact the ADME properties of a drug, creating the potential for improved drug efficacy, safety, and/or tolerability.
- the size and shape of deuterium are essentially identical to those of hydrogen, replacement of hydrogen by deuterium would not be expected to materially affect the biochemical potency and selectivity of the drug as compared to the original chemical entity that contains only hydrogen.
- the variability in deuterium effects has also led experts to question or dismiss deuterium modification as a viable drug design strategy for inhibiting adverse metabolism (see Foster at p. 35 and Fisher at p. 101).
- the compounds of the disclosure are CSF-1R inhibitor compounds as set forth in WO 2017/015267 that are substituted with deuterium and have improved ADME properties, and are in particular, highly resistant to AO degradation, thus potentially improving the drug efficacy and the exposure of the drug in vivo.
- the disclosure relates to a method of treating a disease or disorder mediated by colony stimulating factor-1 receptors (CSF-1R) or a disease or disorder in which CSF-1R is implicated in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound according to Formula (I) or Formula (I’), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- CSF-1R colony stimulating factor-1 receptors
- the disease or disorder is a neurological and immune mediated disease, including Multiple Sclerosis, ALS, MSA, PSP, Huntington’s disease, lupus, lupus nephritis, and rheumatoid arthritis in a subject in need of such treatment comprising administering to the subject an effective amount of a compound according to Formula (I) or Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- a neurological and immune mediated disease including Multiple Sclerosis, ALS, MSA, PSP, Huntington’s disease, lupus, lupus nephritis, and rheumatoid arthritis in a subject in need of such treatment comprising administering to the subject an effective amount of a compound according to Formula (I) or Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- compositions comprising a compound according to Formula (I) or Formula (F).
- FIGS. 1A and IB shows the impact of an exemplary CSF-1R inhibitory compound (Compound 24) on MCP-1 chemokine production following CSF-1 stimulation.
- the mean (FIG 1A) and standard deviation (FIG IB) are shown.
- FIGS. 2A and 2B show the impact of an exemplary deuterated CSF-1R inhibitory compound (Compound 6) on MCP-1 chemokine production following CSF-1.
- the mean (FIG 2A) and standard deviation (FIG 2B) are shown.
- FIGS. 3A and 3B show IC 50 curves for the experiment of Figure 1.
- FIGS. 4A and 4B show IC 50 curves for the experiment of Figure 2.
- FIGS. 5A-5C show the CSF-1R inhibitors Compound 6 (FIG. 5A) and the
- FIGS. 6A-6C show that CSF-1 stimulation significantly increases the Iba1 + area, and treatment with the CSF-1R inhibitors Compound 6 (FIG. 6 A) and control PLX3397 (FIG. 6C) significantly abrogated this effect in a concentration dependent manner. Results for Compound 49 are shown in FIG 6B.
- FIGS. 7A-7C show that CSF-1 stimulation increases the number of cells within the culture (as evidence by DAPI + cells), and that CSF-1R inhibitors Compound 6 (FIG. 7A) and control PLX3397 (FIG. 7C) reduce this number in a concentration dependent manner. Results for Compound 49 are shown in FIG 7B.
- FIGS 8A-8B show cell viability following pre-treatment with DMSO (control) or Compound 6 and CSF-1 stimulation in wild type (FIG 8 A) or SOD1 (FIG 8B) cells.
- FIGS 9A-9B show cell viability following treatment with DMSO (control) or Compound 6 and LPS stimulation in wild type (FIG 9A) or SOD1 (FIG 9B) cells.
- FIGS 10A-10B show MCP-1 production following treatment with DMSO (control) or Compound 6 and CSF-1 stimulation in wild type (FIG 10A) or SOD1 (FIG 10B) cells.
- FIGS 11A-11B show IL-12p40 production following treatment with DMSO (control) or Compound 6 and LPS stimulation in wild type (FIG 11 A) or SOD1 (FIG 11B) cells.
- FIG. 12A shows an in vitro metabolic profile of Compound 24 following incubation in human cryopreserved hepatocytes in the absence of AO inhibitor hydralazine.
- FIG. 12B shows an in vitro metabolic profile of Compound 24 following incubation in human cryopreserved hepatocytes in the presence of AO inhibitor hydralazine.
- FIG. 13 shows proposed metabolic pathways of Compound 24 in cryopreserved human hepatocyctes in the absence and presence of AO inhibitor hydralazine.
- FIG. 14A shows an in vitro metabolic profile of Compound 6 following incubation in human cryopreserved hepatocytes in the absence of AO inhibitor hydralazine.
- FIG. 14B shows an in vitro metabolic profile of Compound 6 following incubation in human cryopreserved hepatocytes in the presence of AO inhibitor hydralazine.
- FIG. 15 shows proposed metabolic pathways of Compound 6 in cryopreserved human hepatocyctes in the absence and presence of AO inhibitor hydralazine.
- FIG. 16 shows cell viability following CSF1R inhibitor treatment and CSF1 stimulation.
- FIG. 17 shows the blocking effect of Compound 6 on CSF1 -induced MCP-1 production in this experiment.
- FIGS. 18A-18B compares MCP1 production of Compound 6 (FIG. 18A) with Compound 24 (FIG. 18B), showing similar effect on MCP1.
- FIGS. 19A-19B show that both CSF1R inhibitors (Compound 6 and Compound 24) significantly mean disease scores.
- the deuterated CSF1R inhibitor, Compound 6, ameliorated paralytic symptoms to a surprisingly greater extent than nondeuterated Compound 24.
- FIG. 20 shows an XRPD pattern of Compound 6 Form A.
- FIG. 21 shows a PLM image of Compound 6 Form A.
- FIG. 22 shows a TGA (top pattern)/DSC (bottom pattern) overlay of
- FIG. 23 shows HPLC of Compound 6 Form A.
- This disclosure relates to colony stimulating factor- 1 receptor inhibitors
- CSF-1R inhibitors that are small molecules capable of penetrating the blood-brain barrier to reach the central nervous system (CNS).
- CNS central nervous system
- This disclosure also relates to pharmaceutical formulations comprising CSF-1R inhibitors and to the use of CSF-1R inhibitors and pharmaceutical compositions comprising CSF-1R inhibitors to treat disease.
- diseases include immune-mediated diseases, including multiple sclerosis, lupus nephritis, rheumatoid arthritis, and neurological diseases, including amyotrophic lateral sclerosis (ALS) and Huntington’s disease.
- ALS amyotrophic lateral sclerosis
- Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the CNS that causes intermittent relapses and progressive neurological deterioration.
- Activated microglial cells and macrophages contribute to CNS damage and play a significant role in disease progression and neurodegeneration in multiple sclerosis.
- These activated innate immune cells can participate in antigen presentation and produce inflammatory and neurotoxic mediators that are destructive to neurons and oligodendrocytes.
- CSF-1R is a receptor-tyrosine kinase expressed on macrophages, monocytes, and microglial cells and represents a potential target for therapeutic modulation of effector function.
- the CSF-1R inhibitors described herein are particularly useful in the treatment of multiple sclerosis, and have demonstrated the following in preclinical in vitro and in vivo studies: a reduction of inflammatory cytokines/chemokines, inhibition of the expansion and activation of macrophages/microglial cells while not negatively affecting their phagocytic activity, an inhibition of CNS infiltration in multiple in vivo disease models, and a therapeutic benefit in mouse disease models.
- CSF-1R antagonism provide neuroprotection in multiple sclerosis by reducing inflammation, demyelination, and axonal loss.
- CSF-1R signaling has also been found to be upregulated in ALS and it may be as well in, e.g., PSP and MSA, and it has been noted in the literature that CSF-1R inhibition appears to be efficacious in preclinical models of ALS, MSA and PSP. See, e.g., Gowing, G. et al., Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase, Exp Neurol. 2009 Dec; 220(2):267-75; Martinez-Muriana, A.
- M-CSF Macrophage colony stimulating factor
- CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves, Sci Rep. 2016 May 13; 6:25663; Neal, M.L. et al., Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration.
- CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019 Oct 1; 142(10):3243-3264; Lodder, C. et al., CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia. Acta Neuropathol Commun. 2021 Jun 8; 9(1): 108.
- the disclosure relates to compounds of Formula (I): and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein: the dashed lines represent optional double bonds;
- X 1 is C, N, or CR 7 ;
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 are each independently selected from N, NR 7 , or CR 7 ;
- X 8 , and X 9 are each independently selected from N or C wherein each R 7 is independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl,(C 2 -C 9 )heteroaryl, (C 2 -C 10 )alkynylamine, (C 1 -C 10 )alkyl-C(O)O-,(C 1 -C 10 )alkoxy-,
- T 1 , T 2 , and T 3 are each independently selected from N or CR 10 , wherein each R 10 is independently selected from H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 2 -C 10 )alkynylamine, (C 1 -C 10 )alkyl-C(O)O-, COOH-(C 1 -C 10 )alkyl-, COOH-(C 3 -C 10 )cycloalkyl-, (C 1 -C 10 )alkoxy-, R 10A -(C 1 -C 10 )alkyl-, R 10A -(C 1 -C 10 )alkylamine, R 10A -((C 1 -C 10 )alkyl) 2 amine, R 1OA -(C 2 -C
- Y 1 is O, NR 12 , or CR 12 R 13 ; wherein R 12 is absent or R 12 and R 13 are each independently selected from H, D, (C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, (C 1 -C 3 )alkynylamine, (C 1 -C 10 )alkoxy-, (C 1 -C 10 )alkoxy-(C 1 -C 10 )alkyl-, HO-, halo, and H 2 N-;
- R 1 and R 2 are each independently selected from H, D, (C 1 -C 10 )alkyl, HO-, halo, and H 2 N;
- R 5 is absent or selected from H, D, (C 1 -C 10 )alkyl, HO-, halo, and H 2 N-; and R 6 is selected from D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, ((C 1 -C 10 )alkyl) 2 amine, R 14 -(C 3 -C 10 )cycloalkyl, R 14 -(C 6 -C 14 )aryl, R 14 -(C 2 -C 9 )heteroaryl, and R 14 -(C 1 -C 10 )alkylamine; wherein R 14 is each independently selected from the group consisting of H, D, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heteroaryl
- Z 1 is selected from H, halo, and (C 1 -C 10 )alkyl
- Y 2 is O, NR 17 , or CR 17 R 18 ; wherein R 17 is absent or R 17 and R 18 are each independently selected from H, (C 1 -C 10 )alkyl, HO-, halo, or H 2 N-; wherein at least one of R 7 , R 1 , or R 2 is D.
- the compounds according to Formula (I) are such that X 1 is N. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 2 is N. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 3 is CR 7 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 4 is CR 7 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 5 is CR 7 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 6 is N.
- the compounds according to Formula (I) are such that X 7 is CR 7 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 8 is C. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 9 is C. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that X 1 is N; X 2 is N; X 3 is CR 7 ; X 4 is CR 7 ; X 5 is CR 7 ; X 6 is N; X 7 is CR 7 ; X 8 is C; and X 9 is C.
- the compounds according to Formula (I) are such that T 1 is CR 10 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that T 2 is CR 10 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that T 3 is CR 10 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that at least two of T 1 , T 2 , and T 3 are each independently CR 10 . In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that T 1 , T 2 , and T 3 are each independently CR 10 .
- the compounds according to Formula (I) are such that each R 10 is independently selected from H, (C 1 -C 10 )alkyl, (C 3 - C 10 )cycloalkyl, (C 1 -C 10 )alkoxy, and halo. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that each R 10 is independently selected from H, (C 1 -C 10 )alkyl, and halo. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that each R 10 is independently selected from H, (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, and halo.
- the compounds according to Formula (I) are such that each R 10 is independently selected from H, (C 1 -C 10 )alkyl, (C 3 -C 10 )cycloalkyl, and halo. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that each R 10 is independently selected from H and halo.
- the compounds according to Formula (I) are such that Y 1 is O. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that Y 2 is O. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that Y1 and Y2 are each O.
- the compounds according to Formula (I) are such that Z 1 is selected from H, halo, and (C 1 -C 10 )alkyl. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that Z 1 is (C 1 -C 10 )alkyl. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that Z 1 is halo. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that Z 1 is H.
- the compounds according to Formula (I) are such that R 1 and R 2 are each independently selected from H and D. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that R 1 and R 2 are both H. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that R 1 and R 2 are both D. In at least one embodiment of the disclosure, the compounds according to Formula (I) are such that one of R 1 and R 2 is H and the other is D.
- the compounds according to Formula (I) are such that R 6 is selected from (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heteroaryl, R 14 -(C 6 -C 14 )aryl, R 14 -(C 2 -C 9 )heteroaryl, and R 14 -(C 1 -C 10 )alkylamine; wherein R 14 is each independently selected from H, (C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamine, (C 1 -C 10 )alkoxy-, HO-, F 2 HC-O-, F 3 C-C(O)-, F 3 C-, and F 2 HC-; and wherein each (C 3 -C 10 )cycloalkyl, or (C 2 - C 9 )heterocycloalkyl are further optionally substituted by one to four groups selected from (C 1 -C 10 )cycloalkyl, (C 2
- the compounds according to Formula (I) are such that R 6 is selected from (C 3 -C 10 )cycloalkyl, and (C 2 -C 9 )heteroaryl; and wherein each (C 3 -C 10 )cycloalkyl, or (C 2 -C 9 )heterocycloalkyl are further optionally substituted by one to two groups selected from (C 1 -C 10 )alkyl, HO-, halo, or H 2 N-.
- the disclosure relates to compounds of Formula (F): and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein: the dashed lines represent optional double bonds;
- A is selected from H and D;
- X 3 is CR 3 wherein R 3 is selected from H and D;
- X 4 is CR 4 wherein R 4 is selected from H, D, and R 7 ;
- X 5 is CR 5 wherein R 5 is selected from H and D, wherein at least one of A, R 3 , R 4 , and R 5 is D.
- the compounds according to Formula (I’) are such that R 1 and R 2 are each independently selected from H and D.
- the compounds according to Formula (F) are such that R 6 is selected from (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heteroaryl, R 14 -(C 6 -C 14 )aryl, R 14 -(C 2 - C 9 )heteroaryl, and R 14 -(C 1 -C 10 )alkylamine; wherein R 14 is each independently selected from H, (C 1 -C 10 )alkyl, (C 1 -C 10 )alkylamine, (C 1 -C 10 )alkoxy-, HO-, F 2 HC-O-, F 3 C-C(O)-, F 3 C-, and F 2 HC-; and wherein each (C 1 -C 10 )alkyl, (C 6
- the compound is selected from 3- (((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6- yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the compound is 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d .
- compositions comprising a pharmaceutically acceptable excipient and a compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises a compound of Formula (I) and/or a pharmaceutically acceptable salt thereof.
- Another aspect of the disclosure is a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least one compound of Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises a compound of Formula (F) and/or a pharmaceutically acceptable salt thereof.
- compositions comprising a pharmaceutically acceptable excipient and a compound of Table A, and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises a compound of Table A and/or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition comprises 3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3- methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d Form A.
- Another aspect of the disclosure is a method of treating a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof comprising administering a therapeutically effective amount of a compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a therapeutically effective amount of a compound of Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a therapeutically effective amount of a compound of Table A, and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the pharmaceutical composition comprises 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3- yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d Form A.
- Another aspect of the disclosure is a method of treating a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of Table A, and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a therapeutically effective amount of a pharmaceutical composition
- a pharmaceutical composition comprising 3-(((2S,3S)-8- methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)- 3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable salts thereof as described herein.
- the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d Form A and/or pharmaceutically acceptable salts thereof as described herein.
- the present disclosure provides a compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use as a medicament.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use as a medicament is a compound of Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use as a medicament is a compound of Table A, and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use as a medicament is a compound selected from 3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the compound comprises 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable salts thereof as described herein.
- the compound comprises 3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo[4,5-b]pyridine-2-d Form A and/or pharmaceutically acceptable salts thereof as described herein.
- the present disclosure provides a compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use in the treatment of a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use in the treatment of a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof is a compound of Formula (F), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use in the treatment of a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof is a compound of Table A, and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein.
- the compound of Formula (I), and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof as described herein for use in the treatment of a disease or disorder, such as neurological and immune mediated diseases, in a subject in need thereof is a compound selected from 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3- yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof.
- the compound comprises 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine-2-d and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable salts thereof as described herein.
- the compound comprises 3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo[4,5-b]pyridine-2-d Form A and/or pharmaceutically acceptable salts thereof as described herein.
- the neurological and immune mediated diseases include multiple sclerosis, ALS, MSA, PSP, Huntington’s disease, lupus, lupus nephritis, and rheumatoid arthritis.
- amino means a functional group having a nitrogen atom and 1 to 2 hydrogen atoms. “Amino” generally may be used herein to describe a primary, secondary, or tertiary amine, and those of skill in the art will readily be able to ascertain the identification of which in view of the context in which this term is used in this disclosure.
- amine or “amine group” or “ammonia group” means a functional group containing a nitrogen atom derived from ammonia (NH3).
- the amine groups are preferably primary amines, meaning the nitrogen is bonded to two hydrogen atoms and one substituent group comprising a substituted or unsubstituted alkyl or aryl group or an aliphatic or aromatic group.
- the amine groups may be secondary amines meaning, the nitrogen is bonded to one hydrogen atom and two substituent groups comprising a substituted or unsubstituted alkyl or aryl groups or an aliphatic or aromatic group, as defined below.
- the amine groups may be tertiary amines meaning the nitrogen is bonded to three substituent groups comprising a substituted or unsubstituted alkyl or aryl groups or an aliphatic or aromatic group.
- the amine groups may also be quaternary amines meaning the designated amine group is bonded to a fourth group, resulting in a positively charged ammonium group.
- any or all of the amines in this disclosure may be in the free amine form (that is, as -NH 2 for a primary amine) or in a protonated form with a pharmaceutically acceptable anion (that is, as -NH3 + Y" for a primary amine, where Y" is the pharmaceutically acceptable anion).
- amide group means a functional group comprising a carbonyl group linked to a nitrogen.
- alkane means a saturated hydrocarbon, bonded by single bonds. Alkanes can be linear or branched. “Cycloalkanes” are saturated hydrocarbons rings bonded by single bonds.
- (C 1 -C 10 )alkyl means a saturated straight chained or branched or cyclic hydrocarbon consisting essentially of 1 to 10 carbon atoms and a corresponding number of hydrogen atoms. Typically, straight chain or branched groups have from one to ten carbons, or more typically one to five carbons. Exemplary (C 1 -C 10 )alkyl groups include methyl (represented by -CH 3 ), ethyl (represented by -CH 2 -CH 3 ), n-propyl, isopropyl, n-butyl, isobutyl, etc. Other (C 1 -C 10 )alkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure.
- (C 2 -C 9 )heteroalkyl means a saturated straight chained or branched or cyclic hydrocarbon consisting essentially of 2 to 10 atoms, wherein 2 to 9 of the atoms are carbon and the remaining atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen.
- Exemplary (C 2 -C 9 )heteroalkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure.
- (C 3 -C 10 )cycloalkyl means a nonaromatic saturated hydrocarbon group, forming at least one ring consisting essential of 3 to 10 carbon atoms and a corresponding number of hydrogen atoms.
- (C 3 -C 10 )cycloalkyl groups can be monocyclic or multicyclic. Individual rings of multicyclic cycloalkyl groups can have different connectivities, for example, fused, bridged, spiro, etc., in addition to covalent bond substitution.
- Exemplary (C 3 -C 10 )cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornanyl, bicyclo-octanyl, octahydro-pentalenyl, spiro-decanyl, cyclopropyl substituted with cyclobutyl, cyclobutyl substituted with cyclopentyl, cyclohexyl substituted with cyclopropyl, etc.
- Other (C 3 -C 10 )cycloalkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure.
- (C 2 -C 9 )heterocycloalkyl means a nonaromatic group having 3 to 10 atoms that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen.
- (C 2 -C 9 )heterocycloalkyl groups can be monocyclic or multicyclic. Individual rings of such multicyclic heterocycloalkyl groups can have different connectivities, for example, fused, bridged, spiro, etc., in addition to covalent bond substitution.
- Exemplary (C 2 -C 9 )heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, azetidinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin- 3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetra
- the (C 2 - C 9 )heterocycloalkyl group is typically attached to the main structure via a carbon atom or a nitrogen atom.
- Other (C 2 -C 9 )heterocycloalkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure.
- the term “aliphatic group” or “aliphatic” means a non-aromatic group consisting of carbon and hydrogen, and may optionally include one or more double and/or triple bonds. In other words, an aliphatic group is any group consisting of carbon and hydrogen which contains no aromatic functionality.
- An aliphatic group may be straight chained, branched or cyclic and typically contains between about one and about 24 carbon atoms.
- aryl group may be used interchangeably with “aryl,” “aryl ring,” “aromatic,” “aromatic group,” and “aromatic ring.”
- Aryl groups include carbocyclic aromatic groups, typically with six to fourteen ring carbon atoms.
- Aryl groups also include heteroaryl groups, which typically have five to fourteen ring atoms with one or more heteroatoms selected from nitrogen, oxygen and sulfur.
- (C 6 -C 14 )aryl means an aromatic functional group having 6 to 14 carbon atoms that form at least one ring.
- (C 2 -C 9 )heteroaryl means an aromatic functional group having 5 to 10 atoms that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen.
- (C 2 -C 9 )heteroaryl groups can be monocyclic or multicyclic. Individual rings of such multicyclic heteroaryl groups can have different connectivities, for example, fused, etc., in addition to covalent bond substitution.
- Exemplary (C 2 -C 9 )heteroaryl groups include furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5
- the (C 2 -C 9 )heteroaryl group is typically attached to the main structure via a carbon atom, however, those of skill in the art will realize when certain other atoms, for example, hetero ring atoms, can be attached to the main structure.
- Other (C 2 -C 9 )heteroaryl groups will be readily apparent to those of skill in the art given the benefit of this disclosure.
- alkynyl means a functional group containing triple bonded carbons, represented by (C 2 -C 10 )alkynyl-.
- alkylamine means an (C 1 -C 10 )alkyl containing a primary, secondary, or tertiary amine group in place of one hydrogen atom, represented by (C 1 -C 10 )alkyl amine and ((C 1 -C 10 )alkyl) 2 amine.
- alkynylamine means a (C 2 -C 10 ) group containing triple bonded carbons and an amine group, represented by (C 2 -C 10 )alkynylamine.
- alkoxy means a (C 1 -C 10 )alkyl bound to an oxygen, represented by (C 1 -C 10 )alkyl-O- or (C 1 -C 10 )alkoxy-.
- alkoxyalkyl means a (C 1 -C 10 )alkyl bound to an oxygen bound to another (C 1 -C 10 )alkyl, represented by (C 1 -C 10 )alkyl-O-(C 1 -C 10 )alkyl- or (C 1 -C 10 )alkoxy-(C 1 -C 10 )alkyl-.
- alkyl ester means a (C 1 -C 10 )alkyl containing an ester group in place of one hydrogen atom, represented by-0(O)C-(C 1 -C 10 )alkyl.
- alkyl acid means an (C 1 -C 10 )alkyl containing a carboxylic acid group in place of one hydrogen atom, represented by (C 1 -C 10 )alkyl-COOH.
- aliphatic acid means an acid of nonaromatic hydrocarbons, represented by (C 1 -C 10 )alkyl-COOH and (C 3 -C 10 )cycloalkyl-COOH.
- dicarbonyl refers to an organic molecule containing two or more adjacent carbonyl groups.
- halo or “Hal” means a fluorine (F), chlorine (Cl), bromine (Br), iodine (I), or astatine (At) ion.
- i- refers to iso.
- methoxy means a (Ci)alkyl containing an oxygen in place of one hydrogen atom, represented by -(O)CH 3 .
- n- refers to normal.
- polyol means an alcohol containing multiple hydroxyl (-OH) groups.
- Steps refers to both enantiomers and diastereomers.
- Substituted means the substitution of a carbon in alkyl, heterocyclic or aryl groups with one or more non-carbon substituents.
- Non-carbon substituents are selected from nitrogen, oxygen and sulfur.
- a 3 to 10-member ring means a closed ring; the 3 to 10-member ring may be acyclic, aromatic or heterocyclic.
- pharmaceutically acceptable anion means an anion that is suitable for pharmaceutical use.
- Pharmaceutically acceptable anions include halides, carbonate, bicarbonate, sulfate, bisulfate, hydroxide, nitrate, persulfate, phosphate, sulfite, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, and cholate.
- Substituted with deuterium refers to the replacement of one or more hydrogen atoms with a corresponding number of deuterium atoms.
- Presently disclosed compounds that are basic in nature are generally capable of forming a wide variety of different salts with various inorganic and/or organic acids. Although such salts are generally pharmaceutically acceptable for administration to animals and humans, it is often desirable in practice to initially isolate a compound from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
- the acid addition salts of the base compounds can be readily prepared using conventional techniques, e.g., by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as, for example, methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
- Acids which can be used to prepare the pharmaceutically acceptable acid addition salts of the base compounds are those which can form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as chloride, bromide, iodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3 -naphthoate)] salts.
- non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions, such as chloride, bromide, iodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate,
- base addition salts can be readily prepared using conventional techniques, e.g., by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
- they also can be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
- stoichiometric quantities of reagents are preferably employed to ensure completeness of reaction and maximum product yields of the desired solid salt.
- Bases which can be used to prepare the pharmaceutically acceptable base addition salts of the base compounds are those which can form non-toxic base addition salts, i.e., salts containing pharmacologically acceptable cations, such as, alkali metal cations (e.g., potassium and sodium), alkaline earth metal cations (e.g., calcium and magnesium), ammonium or other water-soluble amine addition salts such as N-methylglucamine- (meglumine), lower alkanolammonium and other such bases of organic amines.
- pharmacologically acceptable cations such as, alkali metal cations (e.g., potassium and sodium), alkaline earth metal cations (e.g., calcium and magnesium), ammonium or other water-soluble amine addition salts such as N-methylglucamine- (meglumine), lower alkanolammonium and other such bases of organic amines.
- Stereoisomers e.g., cis- and trans- isomers
- optical isomers of a presently disclosed compound e.g., R and S enantiomers
- racemic, diastereomeric and other mixtures of such isomers are within the scope of this disclosure.
- the compounds, salts, prodrugs, hydrates, and solvates presently disclosed can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and geometric isomers and mixtures thereof.
- Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, all tautomers are within the scope of this disclosure.
- Atropisomers are also within the scope of this disclosure. Atropisomers refer to compounds that can be separated into rotationally restricted isomers.
- compositions comprising at least one presently disclosed compound and at least one pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier can be any such carrier known in the art including those described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., (A. R. Gennaro, ed. 1985.)
- Pharmaceutical compositions of the compounds presently disclosed may be prepared by conventional means known in the art including, for example, mixing at least one presently disclosed compound with a pharmaceutically acceptable carrier.
- compositions can be used in an animal or human.
- a presently disclosed compound can be formulated as a pharmaceutical composition for oral, buccal, parenteral (e.g., intravenous, intramuscular or subcutaneous), topical, rectal or intranasal administration or in a form suitable for administration by inhalation or insufflation.
- the compounds presently disclosed may also be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,119,742; 3,492,397; 3,538,214; 4,060,598; and 4,173,626.
- the pharmaceutical composition may take the form of, for example, a tablet or capsule prepared by conventional means with a pharmaceutically acceptable excipient(s) such as a binding agent (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); filler (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricant (e.g., magnesium stearate, talc or silica); disintegrant (e.g., potato starch or sodium starch glycolate); and/or wetting agent (e.g., sodium lauryl sulphate).
- a pharmaceutically acceptable excipient(s) such as a binding agent (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); filler (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricant (e.g., magnesium stearate, tal
- Liquid preparations for oral administration may take the form of a, for example, solution, syrup or suspension, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with a pharmaceutically acceptable additive(s) such as a suspending agent (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicle (e.g., almond oil, oily esters or ethyl alcohol); and/or preservative (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid.)
- a suspending agent e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
- emulsifying agent e.g., lecithin or acacia
- non-aqueous vehicle e.g., almond oil, oily esters
- a proposed dose of a presently disclosed compound for oral, parenteral or buccal administration to the average adult human for the treatment or prevention of a CSF- IR-related disease state is about 0.1 mg to about 2000 mg. In certain embodiments, the proposed dose is from about 0.1 mg to about 200 mg of the active ingredient per unit dose. Irrespective of the amount of the proposed dose, administration of the compound can occur, for example, 1 to 4 times per day.
- compositions and methods of treatment or prevention comprising administering prodrugs of at least one presently disclosed compound are also within the scope of this disclosure.
- Non-limiting examples of suitable CSF-1R inhibitors according to Formula (I) and Formula (I’) are presented in the Examples below. It is understood that any or all of the amines of the structures presented in inhibitors according to Formula (I) and Formula (F) are presented in the Examples below may be in the free amine form or in a protonated form with a pharmaceutically acceptable anion.
- Preferred pharmaceutically acceptable anions include halides, carbonate, bicarbonate, sulfate, bisulfate, hydroxide, nitrate, persulfate, phosphate, sulfite, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, and cholate.
- Most preferred pharmaceutically acceptable anions include chloride, carbonate, and bicarbonate. It is also understood that any or all of the CSF-1R inhibitors according to Formula (I) and Formula (I’) may be the racemate or an enantiomer of the racemate.
- Example 1-1 Preparation of (+/-)-methyl (trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate
- Example 1-2 Preparation of (+/-)-((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanol
- the mixture was quenched by the addition of water (0.12 mL), IN sodium hydroxide solution (0.12 mL), and water (0.38 mL). The resulting mixture was stirred at 0 °C for 10 minutes, and then magnesium sulfate (ca. 5 g) was added. The mixture was filtered through Celite, and the filter cake was washed with ethyl acetate (50 mL).
- Example 1-3 Preparation of (+/-)-5-bromo-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1.4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine
- Example 1-4 Preparation of (+/-)-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2.3-dihydrobenzo [b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine-5-d
- the vessel was sealed, and the contents were degassed under vacuum/backfilled with N 2 (x 3).
- the mixture was heated to 100 °C and was allowed to stir. After 2 h, LC/MS analysis revealed that the reaction was complete.
- the mixture was cooled to room temperature and was concentrated to provide a brown oil.
- Example 2-1 Preparation of 2-bromo-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo[4,5-b] pyridine-5-d
- Example 2-2 Preparation of (+/-)-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine-2,5-d2
- the vessel was sealed, and the contents were degassed under vacuum/backfilled with N 2 (x 3).
- the mixture was heated to 100 °C and was stirred. After 2 h, LC/MS analysis revealed that the reaction was complete.
- the mixture was cooled to room temperature and was concentrated to provide a brown oil.
- Example 3 Synthesis of (+/-)-3-(((trans)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[6][ 1 ,4]dioxin-6-yl)methyl-d2)-3H-imidazo[4,5- 6] pyridine (Compound 3)
- Example 3-1 Preparation of (+/-)-((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methan-d2-ol
- the mixture was quenched by the addition of water (0.50 mL), IN sodium hydroxide solution (0.50 mL), and water (1.5 mL). The resulting mixture was stirred at 0 °C for 15 min, and then magnesium sulfate (ca. 10 g) was added. The mixture was filtered through Celite, and the filter cake was washed with ethyl acetate (100 mL). The filtrate was concentrated to provide
- Example 3-2 Preparation of (+/-)-5-((trans)-6-(azidomethyl-d2)-8- methoxy-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-methoxypyridine
- Example 3-3 Preparation of (+/-)-((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methan-d2-amine
- Example 3-4 Preparation of (+/-)-N-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl-d2)-3- nitropyridin-2-amine
- Example 3-5 Preparation of (+/-)-A 2 -(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl- d2)pyridine-2,3-diamine
- Example 3-6 Preparation of (+/-)-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl-d2)-3H- imidazo [4,5-b] pyridine
- Example 4 Synthesis of (+/-)-3-(((trans)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl-d2)-3H-imidazo[4,5- b]pyridine-2-d (Compound 4)
- Example 4-1 Preparation of (+/-)-2-bromo-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl-d2)-3H- imidazo [4,5-b] pyridine
- Example 4-2 Preparation of (+/-)-3-(((trans)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl-d2)-3H- imidazo [4,5-b] pyridine-2-d
- the vessel was sealed, and the contents were degassed under vacuum/backfilled with N 2 (x 3).
- the mixture was heated to 100 °C in a heating block. After 2 h, LC/MS analysis revealed that the reaction was complete.
- the mixture was cooled to room temperature and was concentrated to provide a brown oil. Chromatographic purification (CombiFlash, 80 g SiO 2 gold column, 20-70% 3: 1 ethyl acetate :ethanol/heptane elute) afforded an impure brown oil.
- Example 5 Synthesis of 3-(((2R,3R)-8-methoxy-2-(6-methoxypyridin-3- yl)-3-methyl-2,3-dihydrobenzo [b][1,4] dioxin-6-yl )met hyl )-3H-iniidazo [4,5-b] pyridine-2- d (Compound 5)
- Example 5-1 Preparation and separation of 3-(((2R,3R)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine and 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-
- (+/-)-3-(((trans)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine was accomplished in five steps from (+/-)-((trans)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methanol (Example 1-2) according to the procedures described in Example 3-2 through Example 3-6.
- the racemic product ( ⁇ 95:5 trans: cis) was subjected to chiral SFC separation (Whelk-01 21 x 250mm column, flow rate 70 mL/min, 50% ethanol in CO 2 /0.1% diethylamine elute, compound (2.24 g) dissolved in 60 mL methanol/15 mL dichloromethane, 1.8 mL of solution per injection) to provide three fractions.
- the first fraction contained a small amount of one of the cis-enantiomers.
- the second fraction contained 3-(((2R,3R)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-
- Example 5-2 Preparation of 2-bromo-3-(((2R,3R)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine
- Example 5-3 Preparation of 3-(((2R,3R)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)niethyl)-3H-imidazo[4,5-b]pyridine-
- Example 6 Synthesis of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)- 3-methyl-2,3-dihydrobenzo [b][1,4] d iox in-6-yl)methyl)-3H-imidazo [4,5-b] pyridine-2-d (Compound 6) Method A:
- Example 6-1 Preparation of 2-bromo-3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine
- Example 6-2 Preparation of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)niethyl)-3H-imidazo[4,5-b]pyridine-
- Example 7 Synthesis of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)- 3-methyl-2,3-dihydrobenzo [b][1,4] dioxin-6-yI)melthy)-3H-imidazo [4,5-b] pyridine-2-d (Compound 6)
- Example 8 Large-Scale Synthesis of 3-(((2S,3S)-8-methoxy-2-(6- methoxypyridin-3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H- imidazo [4,5-b] pyridine-2-d (Compound 6)
- the resulting slurry was solvent exchanged with 2-methyl THF (2 x 250 mL) at below 60 °C to 3.0 to 4.0 volumes. After charging 800 mL(16 vol) of 2-methyl THF, the mixture was warmed to 60 to 65 °C and charged with 50 mL of MeOD and 67 mL (1.0 eq) of a 20% potassium tertiary butoxide solution in THF at 60-65 °C. The reaction mixture was maintained for 3h at 60-65 °C. The reaction was cooled to 20-30 °C, and quenched with 1000 mL (20 vol.) of an aqueous 10% ammonium chloride solution.
- the organic layer was diluted with ethyl acetate and washed with water (3 x 250 mL) and 25% brine solution (250 mL). The organic layer was distilled to 3.0 to 4.0 volumes at 60 °C under vacuum. The mixture was chased with toluene (2 x 250 mL) below 60 °C to 3.0 to 4.0 volumes, chased with heptane (2 x 250 mL) at below 60 °C to 3.0 to 4.0 volumes. The resulting slurry was solvent exchanged with 2-methyl THF (2 x 250 mL) at below 60 °C to 3.0 to 4.0 volumes.
- the mixture was charged with 1050 mL (21 vol) of 2-methyl THF and reaction mass warm up to 60-65 °C to get a clear solution.
- the pale- yellow clear solution that was obtained contained 80-85% D Compound 6 by 1H NMR.
- the solution was charged with 100 mL of MeOD and 13.4 mL (0.2 eq) of 20 % potassium tertiary butoxide solution in THF at 60-65 °C.
- the reaction was maintained for 3 h at 60-65 °C.
- the reaction was cooled to 20-30 °C, and quenched with 500 mL (10 vol.) of 10% ammonium chloride solution.
- the organic layer was further washed with water (3 x 250 mL).
- the organic layer was distilled to 7.5 to 8.0 volumes at 60 °C under vacuum.
- the resulting slurry was refluxed at 65-70°C to get a clear solution.
- the mixture was cooled to 60-65 °C over a period of 20 min and seeded 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][ 1 ,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine- 2-d (0.025 g).
- the mixture was slowly cooled to 25 to 30 °C over a period of 2-3h and further cooled to 0-5 °C over a period of 2-3 h and stirred for 1-2 h.
- the solids were filtered and washed with 50 mL (1.0 vol) of per-chilled 2-methyl THF.
- Example 9 Additional large-scale synthesis advantageously stereoselective for Compound 6
- Example 9-1 Preparation of 2-(5-((3H-imidazo[4,5-b]pyridin-3- yl)methyl)-2-(benzyloxy)-3-methoxyphenoxy)-1-(6-methoxypyridin-3-yl)propan-1-one
- the reactor was purged with nitrogen and charged with hydrogen to 70 psi. After stirring at 70 psi hydrogen pressure at 22 °C for 5 h, HPLC analysis showed the complete consumption of the starting material. Hydrogenolysis was carried out by charging Pd/C (4.8 g, 34 wt%, 5% Pd on active carbon, 50% wet) into the reactor. The Parr reactor was purged with nitrogen and charged with hydrogen to 70 psi. After stirring at 70 psi hydrogen pressure at 22 °C for 48 h, HPLC analysis showed the reaction was essentially completed. The reaction mixture was filtered through a celite pad, washed with isopropanol and methanol. The filtrate was concentrated to a clear yellow oil.
- Example 9-3 Preparation of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo [b] [1,4] dioxin-6-yl)methyl)-3H-imidazo [4,5-b] pyridine
- Tri n-butyl phosphine (11.99 ml; 48.60 mmol; 2.10 eq.) was added dropwise over 10 min with a slight exotherm. The resulting brown solution was stirred at 45-50 °C for 1.5 h.
- sodium hydroxide solution (15 wt%, 40 mL, 6.5 eq.) and the mixture was stirred at 45 °C for 0.5-1 h.
- the reaction was cooled to room temperature. The layers were separated. The aqueous layer was extracted with ethyl acetate (40 mL). The combined organic layers were washed with saturated sodium chloride solution (50 mL), dried over sodium sulfate, filtered and concentrated to a wet-solid.
- Example 9-4 Preparation of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin- 3-yl)-3-methyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]pyridine- 2-d
- the suspension was washed with aqueous 10% w/w ammonium chloride (400 mL).
- the organic layer was separated, diluted with ethyl acetate (200 mL) and washed with water (3 x 100 mL) followed by 1/2 saturated sodium chloride solution (100 mL).
- the organic layer was dried (sodium sulfate), filtered and concentrated to a solid.
- the solid was dried by azeotroping with toluene (2 x 100 mL).
- Samples were dispersed on a microscope slide as slurries or if dry, samples were dispersed with silicone oil and examined under transmitted polarized light.
- HEK293 cells overexpressing human cFMS were cultured in RPMI media in T225 flasks and split twice a week. For the experiment, the cells were trypsinized, counted and diluted with serum-free Megacell media (Sigma Cat# M3817) to 600,000 cells/ml (30,000 cells/well).
- test compounds were prepared by the Echo 555 (LABCYTE) using Echo LDV Plates, Cat# LP- 0200; and 500 nl of each compound concentration was added to 96-well BD Biocoat poly-d- lysine plate (BD Cat#356640) in DMSO (0.5% final). 50 ⁇ L/well MegaCell serum-free media was then added to cover compounds before adding cells at 50 ⁇ L/well cells (30,000/well). The plates were spun down for 1 minute at 1000 rpm and then incubated on benchtop for 15-30 minutes; the plates were moved to a CO 2 incubator at 37°C for overnight incubation.
- White 96-well Perkin Elmer OptiPlates (Cat# 6005509) were pre-coated with 50 ng/well (100 ⁇ L/well) anti-cFMS/CSF-lR (C-20) (Santa Cruz Cat# sc-692) in PBS, sealed with a foil seal, spun down at 1000 rpm for one minute and incubated overnight at 4°C.
- OptiPlates plates were blocked with 200 ul/well 1% BSA in 1x PBST (PBS with 0.1% Triton-X) at room temperature for 2 - 3 hours.
- 100 ⁇ L/well 2x hCSFl (final 150ng/ml) R&D Systems, Cat# 216-MC-025/CF) (or media as a negative control) was added to the HEK293/hFMS cells (BD culture plates) incubated overnight with compounds.
- % response with CSF1 treatment
- 0 % response without CSF1 control columns were used to calculate percent inhibition of tested compounds and a Z' prime value. Plates were incubated at 37°C for 10 minutes.
- Media/hCSFl was aspirated off and cells were lysed with 100 ul/well pre-chilled lysis buffer made up with lysis buffer (Cell Signaling Cat# 9803), protease/phosphatase inhibitors (Pierce Cat#78444), and PMSF (Sigma Cat#93482). Plates were shaken for 60 seconds; then, spun at 3200 rpm for 5 minutes at 4°C and kept on ice. 90 ul of the lysate was transferred to the pre-coated/blocked OptiPlates. The plates were then spun at 1000 rpm for 60 seconds and incubated overnight at 4°C sealed.
- IC 50 values for phosphor c-FMS are provided for selected CSF-1R inhibitors in Table B, below.
- Compound 24 was prepared in accordance with the procedure outlined in Example 1-92 of WO2017/015267.
- Both test compounds were prepared in diluted stock solution (10 mM) with culture media to get a 100 ⁇ M working solution and treated at 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM, 200 nM or 400 nM.
- BV2 mouse microglia were suspended at a concentration of 5 x 10 5 cells/mL and 100 ⁇ L of this cell suspension was added to each well of a 96-well plate. Microglia cells were allowed to rest overnight at 37°C, 5% CO 2 . The following day, the media was removed and cells were treated with either dimethyl sulfoxide (DMSO), Compound 24, or Compound 6 for 30 minutes at 37°C, 5% CO 2 . Cells were then stimulated with 100 ng/mL recombinant mouse M-CSF for 24 hours. After stimulation, the culture supernatant was removed from each well and aliquoted into two different 96-well plates for subsequent ELISA assays.
- DMSO dimethyl sulfoxide
- mouse MCP-1 conjugate 100 ⁇ L of mouse MCP-1 conjugate was added to each well, covered with a new strip of adhesive tape, and incubated at room temperature for 2 hours. After incubation, the plate was washed as described above. Substrate Solution was then added to each well and incubated for 30 minutes at room temperature in the dark. After incubation, the acid stop solution was added to each well, and the plate was read on the ELISA plate reader at 450nm.
- BV2 murine microglia were plated at 50,000 cells per well and rested overnight. Cells were pre-treated with DMSO, Compound 24, or Compound 6 for 30 minutes, and then subjected to CSF-1 stimulation. Cell culture supernatants from this experiment were processed in an MCP1 ELISA to determine whether stimulation/treatment impacted chemokine production. As seen in Figures 1A-1B and Figures 2A-2B, CSF-1 stimulation induced a significant increase in the release of MCP-1 (CCL2 - chemokine) and both small molecule CSF-1R inhibitors significantly reduced MCP-1 production in a concentration dependent manner. Percent inhibition was calculated based upon unstimulated and stimulated controls and IC 50 curves were generated. As seen in Figures 3A-3B and 4A- 4B, both compounds exhibit a similar IC 50 value for this assay between 28.8 nM - 36.5 nM.
- Compound 49 was prepared in accordance with the procedure outlined in Example 1-5 of WO2017/015267.
- test compounds were prepared in diluted stock solution (10 mM) with culture media to get a 100 ⁇ M working solution and treated at 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM, 200 nM or 400 nM.
- Substrate Solution was then added to each well and incubated for 30 minutes at room temperature in the dark. After incubation, the acid stop solution was added to each well, and the plate was read on the FlexStation3 Multi-Mode Microplate Reader (Molecular Devices, cat # Flex3) with SoftMax Pro Software at 450nm.
- CSF-1 stimulation induced a significant increase in the release of MCP-1 (CCL2 - chemokine.
- CSF-1-induced MCP-1 production was not robust in the plate for treated with Compound 49 ( Figure 5B), so an IC 50 value for this compound could not be generated.
- MCP-1 secretion was assessed after 24 hours utilizing R&D MCP-1 Elisa Kit. Each data point represents a single well while graphical columns represent the mean and standard deviation of six wells.
- Ibal + area was quantified following a microglial stimulation assay.
- CSF-1 stimulation significantly increases the Ibal + area and treatment with CSF-1R inhibitors significantly abrogated this effect in a concentration dependent manner.
- Statistical significance was determined by a one-way ANOVA and p values are indicated by * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001, and **** p ⁇ 0.0001.
- DAPI + -labeled nuclei were quantified with following a microglial stimulation assay.
- CSF-1 stimulation increases the number of cells within the culture and CSF-1R inhibitors reducing this number in a concentration dependent manner.
- Statistical significance was determined by a one- way ANOVA and p values are indicated by * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001, and **** p ⁇ 0.0001.
- Lipopolysaccharide from Escherichia coli O55:B5 (Sigma, cat# L6529-lmg, lot#059M4103V) - Made 0.2 mg LPS/mL PBS stock and treated microglia with 10 ng/mL.
- Cell viability was determined using Promega’s Cell Titer Gio Luminescent Cell Viability Assay.
- the assay reagent was first allowed to equilibrate to room temperature for 30 minutes. After culture supernatants were removed, 100 ⁇ L fresh room temperature media was added to each well. Subsequently, 100 ⁇ L of assay reagent was added to each well. The assay plate was then shaken for two minutes and left to rest for 10 minutes. 100 ⁇ L was transferred from each well to a white plate and luminescence was read immediately on the FlexStation3 plate reader.
- mice MCP- 1 conjugate were added to each well, covered with a new strip of adhesive tape, and incubated at room temperature for 2 hours. After incubation, the plate was washed as described above. Substrate Solution was then added to each well and incubated for 30 minutes at room temperature in the dark. After incubation, the acid stop solution was added to each well, and the plate was read on the ELISA plate reader at 450nm.
- mice IL-12p40 conjugate were added to each well, covered with a new strip of adhesive tape, and incubated at room temperature for 2 hours. After incubation, the plate was washed as described above. Substrate Solution was then added to each well and incubated for 30 minutes at room temperature in the dark. After incubation, the acid stop solution was added to each well, and the plate was read on the ELISA plate reader at 450nm.
- CSF-1R inhibitor treatment had no toxic effect on microglia at the concentrations assessed.
- Graphical columns represent the mean and standard deviation of six wells.
- CSF-1R inhibition had no deleterious effect on cell viability.
- Graphical columns represent the mean and standard deviation of six wells. No significant differences were observed in wild-type versus SOD1 microglia cell viability in response to CSF-1 or LPS stimulation.
- Example 13 Caco-2 Permeability and Efflux Assay to compare Compound 6 to Compound 24.
- Caco-2 permeability and efflux assays were performed in cell-based permeability model using Caco-2/TC7 cells.
- Caco-2/TC7 cells were seeded on to Millipore Millicell 96 and for efflux assays, 24-well plates were used. The plates with cells were ready to use between 21-25 days of culturing. Both permeability and efflux assays were performed using the TEC AN automated liquid handling platform.
- test compounds were prepared at 20 ⁇ M test concentrations in permeability assay buffer (10mM HEPES in HBSS buffer, pH 6.5) containing 0.5% BSA.
- Basolateral permeability buffer (pH 7.4) contains 5% BSA.
- test compounds were prepared at 1 ⁇ M test concentrations in permeability assay buffer (10mM HEPES in HBSS buffer, pH 7.4) containing 0.5% BSA.
- the basolateral permeability buffer (pH 7.4) contained 0.5% BSA.
- the permeability assay was initiated by adding 20 ⁇ M test solution to apical side of plate containing Caco-2/TC7 cells.
- 1 ⁇ M test compound was added to an apical compartment for apical to basolateral (A to B) permeability determination.
- Basolateral to apical (B to A) permeability determination the test compound was added to the basolateral side.
- the objective of this assay method was to determine the inhibitory potential of test articles, in vitro, against specific cytochrome P450 (CYP) enzymes, using human liver microsomes (HLMs).
- the test compounds were diluted from pure DMSO stocks to a final test concentration range of 10 ⁇ M - 0.07 ⁇ M in a 0.5% DMSO solution.
- the compounds were co-incubated at 37°C with 0.22mg/mL human liver microsomes (HLMs), 50mM phosphate buffer, 1.33mM NADPH, 3.33mM glucose-6-phosphate, 3.33mM magnesium hexahydrate, 0.4 units/mL glucose-6-phosphate dehydrogenase, and appropriate concentrations of individual chemical probes for 10-30 minutes.
- Incubations were performed in 0.5 million hepatocytes cells/mL at 1 ⁇ M concentration of test compound in duplicate with rat, human, dog, monkey, or mouse hepatocytes, and the concentration-time course of test compound depletion was determined after withdrawing samples from the incubation at assay time points followed by liquid chromatography with tandem mass spectrometry analysis. An organic solvent was used to terminate incubations.
- This method provides a benchmarking tool for an in vitro - in vivo correlation of intrinsic clearance using commercial drugs known to be metabolized by AO.
- Example 14 Metabolite profiles of Compound 24 in human cryopreserved hepatocytes in the absence and presence of the aldehyde oxidase inhibitor hydralazine
- the metabolite profiles of Compound 24 were investigated in vitro in human cryopreserved hepatocytes in the absence and presence of the aldehyde oxidase (AO) inhibitor hydralazine. A total of nine metabolites were identified and quantified by LC-MS following incubation of Compound 24 in human cryopreserved hepatocytes for 2 hours.
- AO aldehyde oxidase
- H10 was proposed to be derived from hydroxylation at the 2C position of the
- H4a was proposed to be derived from hydration at the 3H-imidazole[4,5-b]pyridine moiety and glucuronide at the 2C position of the 3H-imidazole[4,5-b]pyridine moiety of Compound 24.
- Hi la was proposed to be derived from glucuronidation of the 3H-imidazole[4,5-b]pyridine moiety of H10.
- H7 was proposed to be derived from the O-demethylation at 2-methoxyl-pyrindine moiety of Compound 24.
- H6 was proposed to be glucuronide conjugate of Compound 24.
- the proposed major metabolic pathways included AO-mediated hydroxylation followed by glucuronidation and a combination of hydration and glucuronidation.
- Other observed metabolic pathways included non-AO mediated hydroxylation followed by glucuronidation, direct glucuronidation, demethylation followed by glucuronidation, and combinations of oxidative deamination followed by oxidation.
- Compound 24 was prepared in accordance with the procedure outlined in Example 1-92 of WO2017/015267.
- Metabolite identification was performed on UPLC (Thermo Vanquish) coupled with UV (Thermo Vanquish) and mass spectrometry (MS) detection (Thermo Orbitrap ID-X).
- the mass peak areas were used for metabolite profiling, due to low sample concentrations.
- the percentage of metabolite or unchanged parent was calculated based on the total integrated MS peak areas of Compound 24 and its identified metabolites on the assumption of equal mass spectral response for equivalent molar concentration of the metabolites or parent compound.
- Metabolites having a peak area that accounts for equal to or more than 0.1% of the toral integrated MS peaks areas are reported in Table 1 below.
- the metabolites are characterized based on their accurate masses (tolerance ⁇ 5 ppm), mass fragmentation patterns, and comparison with other in vitro studies.
- Table 1 Metabolite profiles of Compound 24 following incubation in human cryopreserved hepatocytes for 2 hours in the absence and presence of hydralazine
- H10 was the most abundant metabolite detected and accounted for 20.3% of the total integrated MS peak areas of Compound 24 and its identified metabolites. Metabolite H4a accounted for 4.5% of the total integrated MS peak areas of Compound 24 and its identified metabolites. Each of other metabolites identified were ⁇ 2% of the total integrated MS peak areas of Compound 24 and its identified metabolites.
- H10 was proposed to be derived from hydroxylation at 2C position of 3H- imidazole[4,5-b]pyridine moiety of Compound 24.
- H4a was proposed to be derived from hydration at 3H-imidazole[4,5-b]pyridine moiety and glucuronide at 2C position of 3H- imidazole[4,5-b]pyridine moiety of Compound 24.
- Hl la was proposed to be derived from glucuronidation of 3H-imidazole[4,5-b]pyridine moiety of H10.
- H7 was proposed to be derived from O-demethylation at 2-methoxyl-pyrindine moiety of Compound 24.
- H6 was proposed to be glucuronide conjugate of Compound 24.
- the proposed major metabolic pathways include AO-mediated hydroxylation followed by glucuronidation and combination of hydration and glucuronidation.
- Other observed metabolic pathways included non-AO mediated hydroxylation followed by glucuronidation, direct glucuronidation, demethylation followed by glucuronidation, and combination of oxidative deamination followed by oxidation.
- Example 15 Metabolite profiles of Compound 6 in human cryopreserved hepatocytes in the absence and presence of aldehyde oxidase inhibitor hydralazine
- the metabolite profiles of Compound 6 were investigated in vitro in human cryopreserved hepatocytes in the absence and presence of aldehyde oxidase (AO) inhibitor hydralazine. A total of nine metabolites were identified and quantified by LC-MS following incubation of Compound 6 in human cryopreserved hepatocytes for 2 hours.
- AO aldehyde oxidase
- H10 was proposed to be derived from hydroxylation at the 2C position of the
- H4a was proposed to be derived from hydration at the 3H-imidazole[4,5-b]pyridine moiety and glucuronide at the 2C position of the 3H-imidazole[4,5-b]pyridine moiety of Compound 6.
- Hl la was proposed to be derived from glucuronidation of the 3H-imidazole[4,5-b]pyridine moiety of H10.
- H7 was proposed to be derived from O-demethylation at the 2-methoxyl-pyrindine moiety of Compound 6.
- H6 was proposed to be a glucuronide conjugate of Compound 6.
- the proposed major metabolic pathways included AO-mediated hydroxylation followed by glucuronidation and a combination of hydration and glucuronidation.
- Other observed metabolic pathways included non-AO mediated hydroxylation followed by glucuronidation, direct glucuronidation, demethylation followed by glucuronidation, and combinations of oxidative deamination followed by oxidation. Incubation conditions
- Metabolite identification was performed on UPLC (Thermo Vanquish) coupled with UV (Thermo Vanquish) and mass spectrometry (MS) detection (Thermo Orbitrap ID-X).
- the mass peak areas are used for metabolite profiling, due to low sample concentrations.
- the percentage of metabolite or unchanged parent was calculated based on the total integrated MS peak areas of Compound 6 and its identified metabolites on the assumption of equal mass spectral response for equivalent molar concentration of the metabolites or parent compound.
- Metabolites having a peak area that accounts for equal to or more than 0.1% of the toral integrated MS peaks areas are reported in Table 2 below.
- Table 2 Metabolite profiles of Compound 6 following incubation in human cryopreserved hepatocytes for 2 hours in the absence and presence of hydralazine
- H10 and H4a were the major metabolites detected and accounted for 6.6% and 4.6% of the total integrated MS peak areas of Compound 6 and its identified metabolites, respectively. Each of other metabolites identified were ⁇ 1% of the total integrated MS peak areas of Compound 6 and its identified metabolites.
- H10 was proposed to be derived from hydroxylation at the 2C position of the
- H4a was proposed to be derived from hydration at the 3H-imidazole[4,5-b]pyridine moiety and glucuronide at the 2C position of the 3H-imidazole[4,5-b]pyridine moiety of Compound 6.
- Hl la was proposed to be derived from glucuronidation of the 3H-imidazole[4,5-b]pyridine moiety of H10.
- H7 was proposed to be derived from (9-demethylation at the 2-methoxyl-pyrindine moiety of Compound 6.
- H6 was proposed to be a glucuronide conjugate of Compound 6.
- the proposed major metabolic pathways include AO-mediated hydroxylation followed by glucuronidation and a combination of hydration and glucuronidation.
- Other observed metabolic pathways included non- AO mediated hydroxylation followed by glucuronidation, direct glucuronidation, demethylation followed by glucuronidation, and combinations of oxidative deamination followed by oxidation.
- Example 16 in vitro Microglia Stimulation Study
- iCell microglia human iPSC derived microglia
- FujiFilm catalog# Cl 110, lot# 105458. These cells were thawed and maintained in iCell Microglia Complete Media according the manufacture instructions.
- iCell microglia were resuspended at a concentration of 5 x 10 5 cells/mL and 100 ⁇ L of this cell suspension was added to the inner 60 wells of a 96-well plate. iCell microglia were allowed to rest overnight at 37°C, 5% CO 2 .
- CellTiter Glo 2.0 Viability Assay [00279] Cell viability was determined using the CellTiter Gio 2.0 Luminescent Cell Viability Assay (Promega, cat# G9242). The assay reagent was first allowed to equilibrate to room temperature for 30 minutes. After culture supernatants were removed, 100 ⁇ L fresh room temperature media was added to each well. Subsequently, 100 ⁇ L of assay reagent was added to each well. The assay plate was then shaken for two minutes and left to rest for 10 minutes. 100 ⁇ L was transferred from each well to a white plate and luminescence was read immediately on the FlexStation3 Multi-Mode Microplate Reader (Molecular Devices, cat # Flex3) with SoftMax Pro Software.
- iCell microglia human iPSC derived microglia
- iCell microglia human iPSC derived microglia
- Media containing growth factors was removed and then the cells were allowed to rest overnight again.
- cells were pre-treated with DMSO or Compound 6 or Compound 24for 30 minutes, and then subjected to CSF1 stimulation.
- Cell viability was assessed utilizing Promega’ s Cell Titer Gio Assay Kit.
- Cell culture supernatants from this experiment were processed in a MCP1 ELISA to determine whether stimulation/treatment impacted chemokine production.
- Figure 16 depicts cell viability following CSF1R inhibitor treatment and CSF1 stimulation as described above. iCell human microglia were plated at 50,000 cells/well and rested overnight following growth factor starvation. Cells were pre-treated with DMSO or RA16100017 for 30 minutes and then subjected to CSF1 stimulation. Cell viability was assessed after 24 hours utilizing Promega’s Cell Titer Glo 2.0 Assay Kit. CSF1 stimulation induced an increase in cell viability and the CSF1R inhibitor had no impact on this effect. Each data point represents a single well while graphical columns represent the mean and standard deviation of six wells.
- FIG. 17 shows the blocking effect of Compound 6 on CSF1 -induced MCP-1 production in this experiment.
- iCell human microglia were plated at 50,000 cells/well and rested overnight following growth factor starvation. Cells were pre-treated with DMSO or RA16100017 for 30 minutes and then subjected to CSF1 stimulation. MCP-1 secretion was assessed after 24 hours utilizing R&D MCP1 Elisa Kit.
- the CSF1R inhibitor treatment significantly reduced MCP1 production in a concentration dependent manner (Ordinary one-way ANOVA). Each data point represents a single well while graphical columns represent the mean and standard deviation of six wells.
- EAE Experimental autoimmune encephalomyelitis
- MOG myelin oligodendrocyte glycoprotein
- MOG35-55 peptide New England Peptides, lot# BU01787) - 250 ⁇ g/mouse in 4 mg/mL complete Freund’s adjuvant (CFA; Chondrex Inc, Cat# 7009, lot# 190446) Bordetella pertussis toxin (PTX, Sigma, cat# P7208-50UG, lot# MKCL 1350) - 280 ng/mouse in 200 ⁇ L PBS
- MOG peptide & CFA subcutaneous injection to 2 sites in the hind flank (100 ⁇ L/site).
- Bordetella pertussis toxin i.v. injection of 280 ng/mouse in 200 ⁇ L PBS on Day 0 and 2.
- CSF1R inhibitor oral gavage every 12 hours
- mice were clinically assessed daily for signs of paralytic disease and weighed intermittently to document weight loss. At study termination, 1/2 brain was fixed for histology and brain/liver/plasma were collected for exposure. Spinal cord and whole blood was collected for flow cytometry. Additional plasma aliquots were saved for follow up analysis.
- mice Female C57BL/6J mice were immunized with an emulsion of MOG35-55 peptide (250 ⁇ g/mouse) in complete Freund’s adjuvant (CFA). The emulsion was delivered by two subcutaneous injections to the hind flank in a volume of 100 ⁇ L per injection site. Bordetella pertussis toxin (PTX) was administered via tail vein injection on Day 0 and Day 2 at a dose of 280 ng/animal in 200 ⁇ L of PBS.
- CFA complete Freund’s adjuvant
- mice were monitored daily for paralytic symptoms and scored for their clinical presentation using a progressive scoring system (Score 0: no disease; Score 1 : flaccid tail; Score 2: hindlimb weakness; Score 3: hindlimb paralysis; Score 4: Front limb weakness or partial paralysis; Score 5: death).
- Score 0 no disease
- Score 1 flaccid tail
- Score 2 hindlimb weakness
- Score 3 hindlimb paralysis
- Score 4 Front limb weakness or partial paralysis
- Score 5 death
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023538678A JP2024500919A (ja) | 2020-12-23 | 2021-12-22 | 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤 |
EP21844906.4A EP4267573A1 (fr) | 2020-12-23 | 2021-12-22 | Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) |
CN202180085787.4A CN116848110A (zh) | 2020-12-23 | 2021-12-22 | 氘代集落刺激因子-1受体(csf-1r)抑制剂 |
US17/669,950 US11530216B2 (en) | 2020-12-23 | 2022-02-11 | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063129939P | 2020-12-23 | 2020-12-23 | |
US63/129,939 | 2020-12-23 | ||
US202163226549P | 2021-07-28 | 2021-07-28 | |
US63/226,549 | 2021-07-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/669,950 Continuation US11530216B2 (en) | 2020-12-23 | 2022-02-11 | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022140528A1 true WO2022140528A1 (fr) | 2022-06-30 |
Family
ID=79730518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/064831 WO2022140528A1 (fr) | 2020-12-23 | 2021-12-22 | Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202241888A (fr) |
WO (1) | WO2022140528A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023249989A1 (fr) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Formes solides d'inhibiteurs du récepteur du facteur-1 de stimulation des colonies deutérées (csf-1r) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3119742A (en) | 1962-12-19 | 1964-01-28 | Smith Kline French Lab | Method of preparing sustained release pharmaceutical pellets and product thereof |
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
WO2016087586A1 (fr) * | 2014-12-04 | 2016-06-09 | Janssen Pharmaceutica Nv | Triazolopyridazine deutérée en tant que modulateur de kinase |
WO2017015267A1 (fr) | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Inhibiteurs du récepteur de facteur-1 de stimulation de colonies (csf-1r) |
-
2021
- 2021-12-22 WO PCT/US2021/064831 patent/WO2022140528A1/fr active Application Filing
- 2021-12-22 TW TW110148210A patent/TW202241888A/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3119742A (en) | 1962-12-19 | 1964-01-28 | Smith Kline French Lab | Method of preparing sustained release pharmaceutical pellets and product thereof |
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
WO2016087586A1 (fr) * | 2014-12-04 | 2016-06-09 | Janssen Pharmaceutica Nv | Triazolopyridazine deutérée en tant que modulateur de kinase |
WO2017015267A1 (fr) | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Inhibiteurs du récepteur de facteur-1 de stimulation de colonies (csf-1r) |
Non-Patent Citations (13)
Title |
---|
BLAKE, MI ET AL., J PHARM SCI, vol. 64, 1975, pages 367 - 91 |
CAS, no. 1391089-35-2 |
FISHER, MB ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, 2006, pages 101 - 09 |
FOSTER, AB, ADV DRUG RES, vol. 14, 1985, pages 1 - 40 |
GOWING, G. ET AL.: "Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase", EXP NEUROL., vol. 220, no. 2, December 2009 (2009-12-01), pages 267 - 75, XP026762277, DOI: 10.1016/j.expneurol.2009.08.021 |
KUSHNER, DJ ET AL., CAN J PHYSIOL PHARMACOL, 1999, pages 79 - 88 |
LODDER, C. ET AL.: "CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia", ACTA NEUROPATHOL COMMUN., vol. 9, no. 1, 8 June 2021 (2021-06-08), pages 108, XP021292134, DOI: 10.1186/s40478-021-01204-8 |
MANCUSO, R. ET AL.: "CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice", BRAIN, vol. 142, no. 10, 1 October 2019 (2019-10-01), pages 3243 - 3264 |
MANEVSKI, N. ET AL.: "Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery", J. MED. CHEM., vol. 62, 2019, pages 10955 - 10994 |
MARTINEZ-MURIANA, A. ET AL.: "CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves", SCI REP., vol. 6, 13 May 2016 (2016-05-13), pages 25663 |
NEAL, M.L. ET AL.: "Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration", FASEB J., vol. 34, no. 1, January 2020 (2020-01-01), pages 1679 - 1694 |
OH, S.J. ET AL.: "Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition", PARKINSON'S ANIMAL MODEL. MOL IMAGING BIOL., vol. 22, no. 4, August 2020 (2020-08-01), pages 1031 - 1042, XP037186997, DOI: 10.1007/s11307-020-01485-w |
ZIENTEK MJIANG YYOUDIM KOBACH RS: "In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase", DRUGMETAB DISPOS, vol. 38, no. 8, 2010, pages 1322 - 1327 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023249989A1 (fr) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Formes solides d'inhibiteurs du récepteur du facteur-1 de stimulation des colonies deutérées (csf-1r) |
Also Published As
Publication number | Publication date |
---|---|
TW202241888A (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11414406B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
EP3703680B1 (fr) | Antagonistes du récepteur muscarinique m4 à l'acétylcholine | |
EP3697781B1 (fr) | Antagonistes du récepteur muscarinique de l'acétylcholine m4 | |
US11225484B2 (en) | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | |
US11325896B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
AU2020401560A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
US20240083907A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
AU2022366992A1 (en) | Integrin inhibitors and uses thereof in combination with other agents | |
WO2022140528A1 (fr) | Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) | |
US11530216B2 (en) | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors | |
CN116848110A (zh) | 氘代集落刺激因子-1受体(csf-1r)抑制剂 | |
US20240010640A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
WO2022261427A1 (fr) | Dérivés de (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phényl)(imino)(méthyl)-lambda6-sulfanone et composés analogues en tant qu'antagonistes du récepteur muscarinique m4 de l'acétylcholine pour le traitement de troubles neurodégénératifs | |
CN118139846A (zh) | 一种egfr小分子抑制剂、含其的药物组合物及其用途 | |
US20240174655A1 (en) | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 | |
JP2023519605A (ja) | 核内受容体に対して活性な化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21844906 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180085787.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023538678 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021844906 Country of ref document: EP Effective date: 20230724 |